Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
view full news & meetings section

Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress


Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new data supporting magnetic resonance imaging (MRI) T2 as a potential marker of clinical outcome in boys with Duchenne Muscular Dystrophy (DMD). Data from ImagingDMD, the largest natural history database of MRI assessments in boys with DMD, demonstrate a strong correlation between a composite of lower leg MRI T2 and boys’ functional abilities. These results highlight the clinical importance of the significant improvement observed in the MoveDMD trial with edasalonexent treatment for lower leg MRI T2 compared to the off-treatment control period. These data were presented today in the late breaking session at the 23rd International Congress of the World Muscle Society in Mendoza, Argentina.

 

https://www.duchennexchange.org/wp-content/uploads/2018/10/Catabasis-logo_RGB-high-res_9-2016.jpg

rareRelated